Finding 961216 (2023-004)

Significant Deficiency Repeat Finding
Requirement
H
Questioned Costs
$1
Year
2023
Accepted
2024-03-26
Audit: 297887
Organization: Legacy Medical Care Inc. (IL)

AI Summary

  • Core Issue: Costs totaling $4,279 were charged to the COVID-19 grant outside the approved period of performance.
  • Impacted Requirements: Non-federal entities must only charge allowable costs incurred during the approved budget period as per federal guidelines.
  • Recommended Follow-Up: Ensure only costs within the period of performance are charged, and for payroll spanning multiple periods, prorate costs based on days worked within the grant period.

Finding Text

Federal Agency: U.S. Department of Health and Human Services Federal Program Name: COVID-19 Vaccines Community-Based Education & Outreach (IVAX) Assistance Listing Number: 93.268 Pass-Through Entity: Illinois Primary Health Care Association Pass-Through Number: N/A Award Periods: July 1, 2022 – March 31, 2023 Type of Finding: Immaterial Noncompliance and Significant deficiency in internal control over compliance Criteria: A non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award's period of performance and any costs incurred before the federal awarding agency or pass-through entity made the federal award that were authorized by the federal awarding agency or pass-through entity (2 CFR sections 200.308 200.309 and 200.403(h)). A period of performance may contain one or more budget periods. Condition: Costs outside of the period of performance were charged to the grant. Questioned Costs: $4,279 Context: Four (4) of seven (7) transactions tested. Cause: Unknown Effect: Legacy may allocate unallowable costs to the federal grant. Repeat Finding: Yes. Prior Year Finding: 2022-004. Recommendation: We recommend that only costs incurred during the period of performance be charged to the grant. For payroll in which periods extend over multiple budget periods, we recommend prorating the amount charged to the grant by days worked within the grant period. Views of Responsible Officials: There is no disagreement with the audit finding.

Categories

Questioned Costs Allowable Costs / Cost Principles Subrecipient Monitoring

Other Findings in this Audit

  • 384770 2023-002
    Significant Deficiency
  • 384771 2023-005
    Material Weakness Repeat
  • 384772 2023-006
    Significant Deficiency Repeat
  • 384773 2023-003
    Significant Deficiency
  • 384774 2023-004
    Significant Deficiency Repeat
  • 961212 2023-002
    Significant Deficiency
  • 961213 2023-005
    Material Weakness Repeat
  • 961214 2023-006
    Significant Deficiency Repeat
  • 961215 2023-003
    Significant Deficiency

Programs in Audit

ALN Program Name Expenditures
93.268 Immunization Cooperative Agreements $210,112
93.323 Epidemiology and Laboratory Capacity for Infectious Diseases (elc) $82,636
93.527 Affordable Care Act (aca) Grants for New and Expanded Services Under the Health Center Program $64,146
93.332 Cooperative Agreement to Support Navigators in Federally-Facilitated and State Partnership Marketplaces $34,711